In the subgroup analysis conducted in patients with European ancestry (Fig. 3; Table 2), the pooled results showed that carriers of CYP2C19 LOF have an increased risk of stroke (RR: 2.69 (1.11–6.51, P = 0.03, Fig. 3A), but not of composite vascular events (Fig. 3B) or bleeding (Fig. 3C) after receiving clopidogrel-based antiplatelet therapy. The gene discussed is CYP2C19; the disease is stroke disorder.